Antares Pharma (ATRS)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
5.59 unch (unch) 05/23/22 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 5.59 unch (unch) -
Fiscal Year End Date: 12/31
| 12-2016 | 12-2015 | 12-2014 | 12-2013 | 12-2012 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 27,715 | 32,899 | 34,029 | 39,067 | 52,097 |
| Marketable Securities | 0 | 15,012 | 6,002 | 24,014 | 21,113 |
| Receivables | 9,073 | 7,953 | 3,510 | 1,035 | 2,229 |
| Inventories | 5,327 | 5,724 | 5,860 | 6,461 | 1,003 |
| Other current assets | 1,773 | 1,199 | 1,914 | 376 | 755 |
| TOTAL | $45,264 | $66,061 | $53,638 | $72,660 | $77,659 |
| Non-Current Assets | |||||
| PPE Net | 17,867 | 14,793 | 10,829 | 6,952 | 3,583 |
| Investments And Advances | 0 | 0 | 0 | 6,008 | 12,016 |
| Intangibles | 3,140 | 3,530 | 3,980 | 2,441 | 2,219 |
| Other Non-Current Assets | 54 | 178 | 326 | 871 | 49 |
| TOTAL | $21,061 | $18,501 | $15,135 | $16,272 | $17,867 |
| Total Assets | $66,325 | $84,562 | $68,773 | $88,932 | $95,527 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 7,885 | 5,188 | 10,072 | 6,379 | 2,865 |
| Accrued Expenses | 5,873 | 6,488 | 5,636 | 5,453 | 2,917 |
| TOTAL | $19,907 | $16,820 | $24,228 | $16,363 | $7,938 |
| Non-Current Liabilities | |||||
| Deferred Revenues | 6,149 | 5,144 | 8,521 | 4,531 | 2,157 |
| TOTAL | $1,200 | $700 | $3,349 | $1,855 | $1,038 |
| Total Liabilities | $21,107 | $17,520 | $27,577 | $18,218 | $8,976 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 155,242 | 154,849 | 131,743 | 129,928 | 126,171 |
| Common Shares | 1,552 | 1,549 | 1,317 | 1,287 | 1,260 |
| Retained earnings | -253,445 | -229,107 | -208,448 | -173,296 | -152,789 |
| Other shareholders' equity | -715 | -692 | -706 | -653 | -665 |
| TOTAL | $45,218 | $67,043 | $41,196 | $70,714 | $86,551 |
| Total Liabilities And Equity | $66,325 | $84,562 | $68,773 | $88,932 | $95,527 |